<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Patient survival and maintenance dialysis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Patient survival and maintenance dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Patient survival and maintenance dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Burkart, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Although maintenance dialysis prevents death from uremia, mortality among patients with end-stage kidney disease (ESKD) remains high. Patients on dialysis have a substantially higher multivariable-adjusted mortality than patients not on dialysis who have cancer, diabetes, or cardiovascular disease [<a href="#rid1">1</a>].</p><p>However, mortality rates among patients with ESKD have improved over time. According to the United States Renal Data System (USRDS) report in 2022, all-cause mortality in patients with ESKD declined steadily between 2010 and 2019, before sharply increasing in 2020, in association with the COVID-19 pandemic [<a href="#rid2">2</a>]. Between 2001 and 2016, adjusted relative mortality rates reported by USRDS declined by 29 percent [<a href="#rid1">1</a>]. Over this period, the adjusted relative reduction in mortality was 28 percent among patients on hemodialysis (HD) and 43 percent among patients on peritoneal dialysis (PD). </p><p>It is well established that suboptimal replacement of native kidney function has an adverse effect on patient survival. This has important implications since more intensive dialysis, particularly above a certain threshold value, may improve survival, such as with short daily or nocturnal HD. </p><p>Additional factors associated with the dialysis procedure may also correlate with decreased survival. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Dialysis vintage is associated with an enhanced risk of death, with each additional year of dialysis treatment associated with an increase in the risk of death of approximately 6 percent [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potassium levels &lt;4.0 or &gt;5.6 mEq/L are associated with increased mortality in patients on HD compared with serum levels between 4.6 and 5.3 mEq/L [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, some, but not all, studies have reported that mortality may be lower among patients on dialysis being treated in not-for-profit facilities compared with those undergoing dialysis in for-profit facilities [<a href="#rid5">5-9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study in the United States, a high nephrologist caseload was associated with a higher patient mortality rate compared with that of patients under the care of nephrologists with lower caseloads [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The size of the dialysis facility may affect mortality. One study of 385,074 patients on dialysis suggested that a higher mortality was observed among patients dialyzed at facilities with &lt;15 stations [<a href="#rid11">11</a>].</p><p></p><p>A review of those factors associated with mortality among patients on dialysis, with an emphasis upon those characteristics related to dialysis itself, will be presented here [<a href="#rid12">12-14</a>].</p><p class="headingAnchor" id="H2"><span class="h1">CAUSES OF DEATH</span><span class="headingEndMark"> — </span>Before discussing the different factors underlying mortality in patients on dialysis, it is helpful to briefly review the major causes of death in this patient population: cardiovascular disease, infection, and withdrawal from dialysis [<a href="#rid15">15-18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular disease accounts for approximately 50 percent of deaths. While a decline in cardiovascular deaths has occurred in the general population, a similar trend has not been observed in patients on dialysis [<a href="#rid15">15</a>]. This discrepancy is in part due to the demographics of patients about to be started on dialysis: Approximately 40 percent are diabetic; the average age is approximately 60 years, and approximately 20 percent are &gt;75 years of age; many patients have underlying cardiac disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections, which are the second most common cause of death, are usually due to common organisms (such as <em>Staphylococcus aureus</em>) and are frequently related to the hemodialysis (HD) vascular access [<a href="#rid19">19</a>]. Among patients on dialysis, infection-related mortality is approximately 20 times higher than in the general population [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/1893.html" rel="external">"Non-access-related infections in patients on chronic dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Withdrawal from dialysis accounts for approximately 15 to 25 percent of patient deaths. (See  <a class="medical medical_review" href="/z/d/html/1877.html" rel="external">"Kidney palliative care: Withdrawal of dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">RISK FACTORS NOT RELATED TO DIALYSIS</span><span class="headingEndMark"> — </span>A large number of risk factors that are unrelated to the dialysis procedure have been associated with decreased survival among patients on dialysis.</p><p class="headingAnchor" id="H4"><span class="h2">Comorbid conditions</span><span class="headingEndMark"> — </span>The presence of comorbid disease is an increasingly common problem, much more prevalent in new patients started on dialysis today than previously [<a href="#rid15">15,18,21-27</a>]. As noted in the 2007 United States Renal Data System (USRDS) Annual Report, diabetes mellitus was the leading cause of end-stage kidney disease (ESKD) in those initiating hemodialysis (HD) (44 percent) [<a href="#rid15">15</a>]. Extended survival at 10 years appears to be less likely for patients with diabetes than those without (4 versus 11 to 14 percent). The 2022 USRDS report observed that approximately 60 percent of patients on dialysis in 2020 had diabetes [<a href="#rid2">2</a>]. </p><p>Heart disease is also very common in the dialysis population. USRDS data suggest that approximately 28 percent of patients with incident ESKD have a history of congestive heart failure [<a href="#rid2">2</a>]. Approximately 80 percent of all patients enrolled in the Hemodialysis (HEMO) Study were noted to have some form of heart disease, with nearly 40 percent having ischemic heart disease [<a href="#rid28">28</a>]. It has also been estimated that only 27 percent of patients about to enter a dialysis regimen have a normal echocardiogram, while 19 percent already have severe left ventricular hypertrophy [<a href="#rid29">29,30</a>]. In addition, as many as 75 percent of the total ESKD population have at least a 50 percent narrowing of at least one coronary artery. Even patients with mild to moderate chronic kidney failure are at markedly increased cardiovascular risk, with chronic kidney disease alone considered a coronary heart disease risk equivalent. (See  <a class="medical medical_review" href="/z/d/html/1960.html" rel="external">"Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"</a> and  <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a>.) </p><p>In addition to antecedent coronary artery disease, additional factors common in patients on dialysis may promote the development of coronary disease and enhanced cardiovascular mortality:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension, which is present in approximately 80 percent of patients at the onset of dialysis and, with effective fluid control, approximately 25 to 30 percent at the end of the first year. (See  <a class="medical medical_review" href="/z/d/html/1848.html" rel="external">"Hypertension in patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic abnormalities, particularly hyperphosphatemia, an elevated calcium phosphorous product, and increased parathyroid hormone (PTH) levels. These extremely common abnormalities are increasingly recognized as possibly important unique risk factors for patients on dialysis. (See  <a class="medical medical_review" href="/z/d/html/1960.html" rel="external">"Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"</a> and  <a class="medical medical_review" href="/z/d/html/7222.html" rel="external">"Vascular calcification in chronic kidney disease"</a> and <a class="local">'Disorders of mineral metabolism'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular hypertrophy, due in part to hypertension, chronic anemia, and perhaps decreased kidney function. (See  <a class="medical medical_review" href="/z/d/html/1846.html" rel="external">"Overview of screening and diagnosis of heart disease in patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperlipidemia. (See  <a class="medical medical_review" href="/z/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus, which is a major risk factor for coronary artery disease (in patients with and without kidney failure) and is common among patients requiring dialysis. (See  <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">"Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus"</a>.)</p><p></p><p>The concurrent presence of other life-threatening conditions will also affect overall survival [<a href="#rid25">25,27,31-33</a>]. In an extensive analysis of Dialysis Outcomes and Practice Patterns Study (DOPPS) data, 17 comorbid conditions accounted for nearly all of the total variance that predicted survival among patients on HD [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Underlying kidney disease</span><span class="headingEndMark"> — </span>Five-year survival among patients on dialysis is best with chronic glomerular diseases and polycystic kidney disease (PKD), intermediate with hypertension-induced kidney disease, and worst with diabetic nephropathy [<a href="#rid15">15,34</a>]; five-year survival of the patient with diabetic nephropathy is only 20 percent [<a href="#rid15">15,34</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Age</span><span class="headingEndMark"> — </span>Survival declines with increasing age, with patients &lt;45 years of age doing best [<a href="#rid15">15,21,34,35</a>]. Older patients with renal vascular disease appear to have the worst prognosis, with such patients having 5- and 10-year survival rates of only approximately 15 and 5 percent, respectively. In one prospective study from Canada, these older patients were frequently not offered dialysis as possible therapy [<a href="#rid36">36,37</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Country</span><span class="headingEndMark"> — </span>Survival among patients on dialysis has been substantially lower in the United States than in Europe and Japan [<a href="#rid21">21,25,35,38,39</a>]. Some evidence suggests that this is due in part to general differences in mortality (particularly that due to cardiovascular disease) among the general population in various countries [<a href="#rid40">40,41</a>]. In one European study that adjusted for age, sex, and diabetes, for example, approximately 25 percent of the difference in mortality among patients on dialysis between the northern and southern areas of Europe could be attributed to differences in mortality in the general population of these areas [<a href="#rid41">41</a>].</p><p>Differences in mortality in various countries and geographic regions therefore cannot be entirely explained by differences among patients that are unrelated to dialysis itself. These include variations among comorbid conditions (with increased incidence of diabetes, psychiatric diseases, and cardiovascular disease [heart failure and peripheral vascular disease] in the United States); patient age (which tends to be higher in the United States); racial or genetic differences; other demographic factors; and differences in transplantation rate (low rate in Japan) [<a href="#rid25">25,39</a>].</p><p>Other factors that may contribute to the differences in survival include variations in underlying kidney disease (such as increased incidence of immunoglobulin A [IgA] nephropathy in Japan) and differences in thresholds for accepting patients for dialysis [<a href="#rid39">39</a>]. Another factor may be differences in adherence to the dialysis schedule; in some countries such as Japan, nonmedical reasons for a missed treatment are highly uncommon, compared with the United States [<a href="#rid42">42</a>]. A decline in the relative mortality rates in the United States may reflect the consistent widespread improvement in the overall quality of the national dialysis prescription [<a href="#rid15">15</a>]. (See <a class="local">'Improved survival with more intensive dialysis'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Race</span><span class="headingEndMark"> — </span>As a group, African Americans and Asian Americans have a lower mortality rate than White patients [<a href="#rid15">15,43-45</a>]. In one study, the survival rates of Black patients, White patients, and patients of other races at five years were 35, 25, and 32 percent, respectively. Similar relative results were observed in a single-center study, which reported 47 and 36 percent survival rates at five years for Black patients and White patients, respectively [<a href="#rid46">46</a>]. In initial studies, this survival advantage appeared to persist after adjustment for patient characteristics, comorbidities, and laboratory abnormalities [<a href="#rid43">43,47</a>].</p><p>However, in subsequent studies, the survival advantage was markedly attenuated or lost in multivariate analyses that adjusted for other patient variables [<a href="#rid48">48,49</a>]. As an example, in an analysis of outcomes of 1,330,007 patients identified in the USRDS, although the survival of Black patients as a group was better compared with White patients, this advantage was modified by age [<a href="#rid49">49</a>]. Whereas a survival advantage persisted for Black patients &gt;50 years of age, Black patients &lt;50 years of age had higher mortality compared with White patients, particularly when transplantation was factored in as a competing risk.</p><p>The underlying reasons for increased survival among older Black patients are unclear. One possibility is that mortality among Black patients with predialysis chronic kidney disease (CKD) is much higher than among White patients with predialysis kidney disease, resulting in the selection of relatively "healthier" patients who eventually require dialysis. This, in turn, would result in an apparent survival advantage among Black patients with ESKD. Support for this hypothesis was provided by a study of participants of the Third National Health and Nutrition Examination Survey (NHANES), in which a higher risk for death in the early stages of CKD was observed among Black patients [<a href="#rid50">50</a>]. Another possibility is that Black patients on dialysis may have a relatively greater use of activated vitamin D therapy, a modality indirectly linked with improved survival [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Psychosocial factors</span><span class="headingEndMark"> — </span>Psychosocial factors also appear to significantly affect mortality, independent of the presence of other comorbid conditions. Increased levels of social support, enhanced behavioral compliance, and positive perceptions of the effects of illness are all associated with a decreased risk of dying [<a href="#rid52">52</a>]. Their effect on mortality appears to be equivalent to those of medical risk factors. (See  <a class="medical medical_review" href="/z/d/html/4855.html" rel="external">"Psychiatric illness in adults receiving maintenance dialysis"</a>.)</p><p>Location of residence may alter survival. Residence in areas with higher median household income has been associated with improved survival and, among Black patients, residence in highly segregated areas with increased mortality [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Nutrition</span><span class="headingEndMark"> — </span>There is greater medical risk and increased mortality in undernourished patients, particularly those with hypoalbuminemia. Although these observations have primarily been made in patients on maintenance HD and are related to the dialysis dose (see <a class="local">'Malnutrition'</a> below), the presence of malnutrition prior to the initiation of dialysis is strongly predictive of increased mortality with the onset of dialysis [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H617445752"><span class="h2">Salt intake</span><span class="headingEndMark"> — </span>A post-hoc analysis of the HEMO Study including 1770 patients on HD has suggested that higher reported dietary sodium intake and the ratio of sodium to calorie or potassium intake are associated with increased all-cause mortality and a slightly increased ultrafiltration requirement [<a href="#rid55">55</a>]. Reported sodium intake was not associated with predialysis systolic blood pressure. Prescribed sodium restriction was not associated with mortality, systolic blood pressure, or ultrafiltration requirement in this study. This study is somewhat limited by the use of dietary recall, which may have underestimated both sodium and calorie intake [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H14176514"><span class="h2">Residual kidney function</span><span class="headingEndMark"> — </span>Residual kidney function is associated with improved survival of patients on dialysis. Among patients on peritoneal dialysis (PD), the beneficial effect of continued urine output on survival has been shown in multiple studies. (See  <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis"</a>.)</p><p>The following studies suggest that preserved kidney function is associated with improved survival among HD patients [<a href="#rid57">57-60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 650 patients on incident HD, mortality was significantly lower at 6, 12, and 24 months after dialysis was initiated among those with residual kidney function versus those without; this benefit was maintained after correcting for albumin, age, comorbidities, hemodiafiltration, and underlying kidney disease [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Netherlands Cooperative Study on the Adequacy of Dialysis among 740 patients on HD, survival was directly related to preserved kidney function [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 734 patients on incident HD, the presence of urine output at one year after dialysis initiation, compared with those without residual function, was significantly associated with a lower all-cause mortality (hazard ratio [HR] 0.70, 95% CI 0.52-0.93) and a trend toward decreased cardiovascular mortality (HR 0.69, 95% CI 0.45-1.05) [<a href="#rid60">60</a>].</p><p></p><p>The benefit of residual kidney function on cardiovascular survival is likely multifactorial. It may be via improved chronic regulation of fluid and electrolyte balance. Patients who have a preserved urine output may accumulate less fluid in the interdialytic period and, therefore, will have less time spent in a state of volume overload. They also will require less fluid removal during dialysis, which at times may occur too rapidly. Another possibility is that residual kidney function allows increased removal of protein-bound uremic toxins, some of which have a potential for adverse cardiovascular effects [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Others</span><span class="headingEndMark"> — </span>The effect on mortality of a number of additional patient characteristics has been assessed, primarily in observational cohort studies; to what extent there is a direct cause-and-effect relationship between these characteristics and mortality amongst ESKD patients is largely unknown.</p><p class="bulletIndent1"><span class="glyph">●</span>Inflammation – Patients on dialysis with evidence of an ongoing inflammatory state have an enhanced mortality. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1939.html" rel="external">"Inflammation in patients with kidney function impairment"</a> and  <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum cardiac enzymes – Elevations of cardiac troponin T (cTnT) among asymptomatic patients on chronic dialysis are associated with decreased survival. The exact source of cTnT in this setting and the reasons for the correlation between elevated levels and a poor prognosis are unknown. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1920.html" rel="external">"Cardiac troponins in patients with kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1892.html" rel="external">"Clinical manifestations and diagnosis of coronary artery disease in end-stage kidney disease (dialysis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sleep disorder – The presence of a sleep disorder enhances the risk of death in patients without kidney failure (see  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>). A paucity of data exists concerning their effect upon survival in patients undergoing maintenance dialysis. Limited observational evidence suggests that the presence of periodic limb movements in sleep, the total number of arousals, and a decline in sleep quality during the first year on dialysis may strongly and independently correlate with near-term mortality [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Predialysis care – An increasing number of studies, although all observational and retrospective, suggest that patients referred late to a nephrologist for predialysis medical care, compared with those referred early in the disease course, have an enhanced mortality risk once dialysis is initiated. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a>.)</p><p></p><p class="bulletIndent1">There is marked variability in the quality of predialysis care based upon the medical center and geographic area. In the United States, there also appears to be geographic clustering of centers with increased mortality and less-than-adequate predialysis care [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin levels – A discussion of the role of low hemoglobin levels in association with mortality among patients with kidney disease is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1">There is also some evidence that variability in hemoglobin levels increases mortality in ESKD [<a href="#rid65">65-67</a>]. This was shown in a retrospective cohort study of 34,963 patients on HD in which survival analysis found that each 1 g/dL increase in hemoglobin variability (defined by the residual standard deviation) was associated with a 33 percent increase in the death rate [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fractures – Patients with ESKD have an increase in risk of bone fractures, with fractures of pelvis/hip being most common [<a href="#rid68">68,69</a>]. Among such patients, hospitalizations for fractures (particularly vertebral, shoulder/upper arm, or pelvis/hip) are associated with a relatively high one-year mortality rate [<a href="#rid69">69-71</a>]. In a study from the USRDS, patients on dialysis with a hip fracture had a twofold higher risk of death than those matched controls without a fracture [<a href="#rid71">71</a>]. Risk factors for falling include older age, diabetes, high number of prescribed oral drugs, antidepressant use, and inability to walk without significant help [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frailty – Frailty is commonly defined by the presence of three or more of the following: weight loss, muscle weakness, fatigue or exhaustion, low physical activity, and slow gait. Independent of age, increased mortality is noted among frail patients on dialysis. As an example, based upon data from 2275 adults from the dialysis Wave II study, a higher risk of death was noted among those defined as frail (adjusted HR 2.24, 95% CI 1.60-3.15) [<a href="#rid72">72</a>]. A subsequent meta-analysis also reported that frailty was associated with an increased risk of mortality [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonadherence – Nonadherence to the dialysis regimen, which can be defined in part by regularly skipping HD sessions and/or poor adherence to dietary restrictions, is not uncommon [<a href="#rid42">42</a>]. It is associated with increased mortality [<a href="#rid74">74</a>]. In a study of 739 patients, of whom 67 were classified as skippers (absent &gt;3 percent of treatments), increased mortality was associated with skipping (HR 1.69, 95% CI 1.23-2.3) [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical activity – Habitual physical activity has been associated with decreased mortality among patients undergoing maintenance HD [<a href="#rid75">75-78</a>]. As an example, among 202 outpatients on HD, at a median follow-up of 45 months, mortality risk decreased with increased physical activity, as quantitated by an accelerometer (HR per 10 min/day increase in physical activity 0.78, 95% CI 0.66-0.92) [<a href="#rid77">77</a>]. A similar observation was made in the Comprehensive Dialysis Study, in which, among 1554 ambulatory dialysis patients, lower physical activity, estimated using the 94-item Human Activity Profile (HAP), was associated with increased mortality [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional features – A large number of additional patient characteristics and/or agents are reportedly associated with mortality. These include periodontal disease, <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a>, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, and high blood lead levels [<a href="#rid79">79-82</a>].</p><p></p><p>The remainder of this topic review will focus upon those factors largely unique to the dialysis procedure that affect patient mortality.</p><p class="headingAnchor" id="H12"><span class="h1">ADEQUACY OF DIALYSIS</span><span class="headingEndMark"> — </span>The higher mortality rate in the United States was thought to be related at least in part to <strong>inadequate dialysis</strong>. The weekly hemodialysis (HD) times declined progressively in the United States from 25 to 40 hours in the 1960s, to 12 to 15 hours in the 1970s and 1980s, to as low as 7 to 8 hours in the 1990s [<a href="#rid83">83,84</a>]. This decreasing time likely contributed to higher mortality, as suggested by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Studies in both Germany and the United States have documented the relationship between shorter dialysis time and poorer outcome [<a href="#rid85">85,86</a>]. Patients dialyzed &lt;3.5 hours three times per week have approximately twice the mortality risk compared with patients dialyzed four or more hours three times per week [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Historically, the group from Tassin, France has reported one of the best dialysis survival estimates of any program or registry, with a 15-year survival rate of 65 percent in 445 patients followed from 1970 through 1990  (<a class="graphic graphic_figure graphicRef53811" href="/z/d/graphic/53811.html" rel="external">figure 1</a>) [<a href="#rid35">35</a>]. These patients, who were dialyzed very intensively (Kt/V of 1.67), also had a high incidence of full rehabilitation, and almost all patients were rendered normotensive on no antihypertensive medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar benefits with longer times on dialysis have been observed among patients undergoing nocturnal HD and short daily HD. (See  <a class="medical medical_review" href="/z/d/html/1959.html" rel="external">"Outcomes associated with nocturnal hemodialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1898.html" rel="external">"Short daily hemodialysis"</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Historic overview of survival and Kt/V</span><span class="headingEndMark"> — </span>The utilization of urea kinetic modeling and the Kt/V index was in part responsible for the decreasing HD time and concomitant increase in mortality in the United States. Urea kinetic modeling became widely applied after the results of the National Cooperative Dialysis Study (NCDS) were published [<a href="#rid87">87-89</a>]. The NCDS found that a Kt/V urea &gt;0.9 with thrice weekly treatment provided an "adequate" dialysis prescription in that the patient failure rate of 13 percent was substantially below that in patients with a lower Kt/V. (See  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a>.)</p><p>Although the NCDS included no patients with diabetes or those with other important comorbid conditions, a Kt/V of 1.0 was widely accepted as representing adequate dialysis. Shorter dialysis times were permitted as long as the goal Kt/V was attained. However, this goal was quite arbitrary since no attempt was made in the NCDS to determine whether a higher Kt/V might be associated with further clinical, biochemical, or rehabilitative improvement.</p><p class="headingAnchor" id="H14"><span class="h3">Improved survival with more intensive dialysis</span><span class="headingEndMark"> — </span>Subsequent observational data suggested that a higher Kt/V was beneficial. Excellent survival rates have been reported in Tassin, France (Kt/V &gt;1.6) and Minnesota, United States (Kt/V &gt;1.3), where patients, even those in high-risk groups, were more intensively dialyzed [<a href="#rid35">35,90</a>]. Urea kinetic modeling was utilized, but attention was paid to all the details involved in delivering a more optimal dialysis prescription. This improvement in survival occurred despite a striking increase in comorbidity, which itself would have decreased survival [<a href="#rid90">90</a>].</p><p>Similar findings were reported in a retrospective analysis of 13,473 patients, in which patient outcome was compared with dialysis intensity. Patient survival was significantly reduced at urea reduction ratios (URRs) &lt;60 percent (Kt/V &lt;1.20) [<a href="#rid91">91</a>]. A definition of the URR can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a>.)</p><p>A number of observational studies were compatible with the hypothesis that more intensive dialysis leads to improved survival:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, increasing the mean Kt/V from 0.82 (pre-1988) to 1.33 led to a reduction in the gross mortality rate from 22.8 down to 9.1 percent per year [<a href="#rid92">92</a>]. This was associated with increases in protein catabolic rate from 0.83 to 1.0 (an index of protein intake (see  <a class="medical medical_review" href="/z/d/html/1841.html" rel="external">"Protein intake in patients on maintenance hemodialysis"</a>)) and in plasma albumin concentration from 3.5 to 3.9 g/dL (35 to 39 g/L). Thus, enhanced nutrition probably contributed to the improvement in survival (see <a class="local">'Malnutrition'</a> below). However, increasing the degree of dialysis was associated with the use of biocompatible HD membranes; it is therefore possible that the observed benefits were due at least in part to avoidance of bioincompatible membranes. (See <a class="local">'Hemodialysis membranes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report, increasing the mean Kt/V from 1.18 (pre-1989) to 1.46 (and the URR from 61 to 70 percent) led to a reduction in the gross mortality rate from 22.5 down to 18.1 percent per year [<a href="#rid93">93</a>]. This improvement was achieved with standard cellulosic bioincompatible membranes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A national sample in the United States suggested a 7 percent reduction in mortality for each 0.1 unit increase in Kt/V  (<a class="graphic graphic_figure graphicRef77222" href="/z/d/graphic/77222.html" rel="external">figure 2</a>) [<a href="#rid94">94</a>]. Although no statistically significant benefit was noted above a Kt/V of 1.3, a projected trend favoring an increased benefit with increasing dialysis was observed above this dialysis level.</p><p></p><p>A difficulty concerning the optimal dialysis dose was that some [<a href="#rid95">95,96</a>], but not all [<a href="#rid97">97</a>], studies observed an increased relative risk (RR) of death among patients with extremely high values for Kt/V (&gt;1.6) or the URR (URR between 75 and 79 percent). Since these values reflect increased urea clearance and/or an extremely low body volume (which may represent poor nutrition), the increased death rate may have been due to the effects of marked malnutrition.</p><p>Support for this hypothesis comes from a study that evaluated the correlation between mortality, dialysis dose, and body volume in over 3000 patients on dialysis [<a href="#rid96">96</a>]. Consistent with previous reports, patients with a Kt/V or URR value in the highest (fifth) quintile had an increased RR of death (19 percent greater than those in the third quintile). However, a higher Kt alone was not associated with an increased RR of death, as there was a 2 percent decrease in mortality risk per liter increase in clearance.</p><p>These observations, in combination with the finding that patients in the fifth quintile suffered from more severe protein-calorie malnutrition, suggest that the increased mortality associated with very high Kt/V or URR values may reflect poor nutrition. Such findings support the use of alternative measures of dialysis adequacy, such as the Kt alone. (See  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a>.)</p><p>Based upon these observational studies, the optimal level of HD and the best measure of HD adequacy were <strong>therefore undefined</strong>. Statistical analysis of the previous studies, as well as others by Gotch et al, suggested that faulty methodology may have supported the conclusion that increasing dialysis equals increasing survival [<a href="#rid98">98</a>]. The above studies were also retrospective in design and ignored the wide variation in dialysis delivery.</p><p class="headingAnchor" id="H531156266"><span class="h3">Limitations of Kt/V</span><span class="headingEndMark"> — </span>Urea kinetic modeling is the preferred method for measuring the dialysis dose. However, despite its value as a practical guide to dialysis treatment, Kt/V does not account for the following factors that appear to affect survival (see  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis", section on 'Limitations'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Clearance of different-sized solutes (such as middle molecules). (See  <a class="medical medical_review" href="/z/d/html/1916.html" rel="external">"Uremic toxins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapidity of fluid removal during HD. (See <a class="local">'Rapid ultrafiltration'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Residual kidney function in patients on HD. In contrast to patients on peritoneal dialysis (PD), in whom residual kidney function is considered when assessing dialysis adequacy, most nephrologists do not include urinary clearance of urea when determining Kt/V. However, this may be changing. (See  <a class="medical medical_review" href="/z/d/html/97967.html" rel="external">"Incorporating residual kidney function into the dosing of intermittent hemodialysis"</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h2">HEMO Study</span><span class="headingEndMark"> — </span>In an attempt to overcome these difficulties concerning survival and dialysis dose (as well as survival and low- and high-flux dialysis membranes), a large, prospective, clinical trial called the Hemodialysis (HEMO) Study was performed [<a href="#rid99">99</a>]. In this study, 1846 patients were randomly assigned to a standard or high dose of dialysis <strong>and</strong> a low- or high-flux dialyzer. The standard-dose goal was an equilibrated Kt/V of 1.05, which is equivalent to a URR of 65 percent or a single-pool Kt/V of 1.25. The high-dose goal was an equilibrated Kt/V of 1.45, which is the same as a ratio of 75 percent or a single-pool Kt/V of 1.65. The primary outcome was death from any cause, while the main secondary outcomes were the rate of all hospitalizations (but excluding those related to access) and the composite outcomes of the first hospitalization for a cardiac problem or death from any cause, the first hospitalization for an infectious cause or death, and the first decline of &gt;15 percent of the serum albumin from baseline value or death.</p><p>The following results concerning dialysis dose were reported at a mean follow-up of 4.5 years:</p><p class="bulletIndent1"><span class="glyph">●</span>Impressive separation was obtained. The standard-dose group received an equilibrated Kt/V of 1.16, a single-pool Kt/V of 1.32, and a URR of 66.3 percent, while the high-dose group had values of 1.53, 1.71, and 75.2 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of death from any cause, the primary outcome, was the <strong>same</strong> in the high- and standard-dose groups (RR 0.96 for high versus standard dose, CI 0.84-1.10).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of the main secondary outcomes (as previously delineated) was also the <strong>same</strong> for both dialysis doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subgroup analysis revealed a significant survival benefit for <strong>women</strong> receiving a high-dialysis dose (19 percent lower risk of death than women in the standard-dose group). However, men receiving high-dose dialysis had a 16 percent higher risk of death than those receiving standard-dose dialysis.</p><p></p><p>Subsequent analysis found that differences in dialysis dose also had no effect upon the incidence of infection-related deaths [<a href="#rid100">100</a>].</p><p>Thus, patients on HD on a three treatment per week schedule <strong>do not</strong> appear to derive a major benefit from a higher than standard dialysis dose (in terms of Kt/V urea), as recommended by the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines. (See  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a> and <a class="local">'Summary and recommendations'</a> below.)</p><p>Some data suggest that mortality among patients in dialysis centers with the highest percentage of patients who exceed KDOQI guidelines (URRs of &gt;65 percent) is lower than in those with fewer patients who achieve these ratios. As an example, based upon data from 2858 United States dialysis facilities from 1999 to 2002, those centers in the lowest quintile for the percentage of patients with higher than recommended URRs had 22 percent higher mortality rates than those in the highest quintile [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Peritoneal dialysis</span><span class="headingEndMark"> — </span>Among patients treated with PD, a similar correlation between the degree of solute clearance (measured weekly either by Kt/V or the creatinine clearance) and survival was also postulated to exist. This hypothesis was supported by the results of a prospective, cohort, multicenter study in Canada and the United States (CANUSA) that evaluated the relationship of the adequacy of dialysis and nutritional status to mortality, morbidity, and technique failure.</p><p>However, survival in this study was related to residual kidney function (which changed over time) and <strong>not</strong> to peritoneal clearance alone (which did not change). Confirmation that an increase in peritoneal clearance alone (beyond a minimum threshold value) is not a principal factor underlying survival was provided by the Adequacy of Peritoneal Dialysis in Mexico (ADEMEX) trial. Instead, subsequent analysis of this trial found that measures of health-related quality of life significantly predicted patient survival [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">HEMODIALYSIS MEMBRANES</span><span class="headingEndMark"> — </span>Survival, dialysis adequacy, and the biocompatibility of hemodialysis (HD) membrane may all be closely interrelated. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1873.html" rel="external">"Clinical consequences of hemodialysis membrane biocompatibility"</a>.)</p><p>Differences in survival may also be due to variations in the ability of HD membranes to remove molecules larger than urea, the so-called middle molecules. High-flux membranes are better able to remove such substances, compared with that observed with low-flux membranes. Whether survival differs upon exposure to high- and low-flux membranes was also evaluated in the Hemodialysis (HEMO) Study, in which nearly 2000 patients were randomly assigned to a standard or high dose of dialysis <strong>and</strong> a low- or high-flux dialyzer (based on clearance of beta-2-microglobulin) [<a href="#rid99">99</a>]. The primary outcome was death from any cause, while the main secondary outcomes were the rate of all hospitalizations (but excluding those related to access) and the composite outcomes of the first hospitalization for a cardiac problem or death from any cause, the first hospitalization for an infectious cause or death, and the first decline of &gt;15 percent of the serum albumin from baseline value or death. The results and discussion relating to survival and dialysis dose can be found elsewhere in this topic review. (See <a class="local">'HEMO Study'</a> above.)</p><p>With respect to dialysis membranes, the following results were reported at a mean follow-up of 4.5 years:</p><p class="bulletIndent1"><span class="glyph">●</span>Impressive separation was obtained as the low- and high-flux groups had clearances of beta-2-microglobulin of 3 and 34 mL/min, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of death from any cause, the primary outcome, was the <strong>same</strong> in the high- and low-flux groups (relative risk [RR] 0.92).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of the main secondary outcomes (as previously delineated) was also the <strong>same</strong> for both flux groups. In the high-flux group, there were significant reductions, compared with the low-flux group, in the risk of death from cardiac causes and the combined outcome of first hospitalizations or death from a cardiac cause [<a href="#rid28">28</a>]. However, as previously mentioned, total mortality was the same in both flux groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subgroup analysis revealed a significant survival benefit for patients with &gt;3.7 years of dialysis receiving high-flux dialysis (32 percent lower risk than the low-flux group). However, men receiving high-dose dialysis had a 16 percent higher risk of death than those receiving standard-dose dialysis, and the strength of the interaction between flux and years of dialysis was weakened when years of dialysis was treated as a continuous variable.</p><p></p><p>Subsequent analysis found that differences in dialysis membrane also had no effect upon the incidence of infection-related deaths [<a href="#rid100">100</a>].</p><p>Thus, as noted in the HEMO Study, survival was the <strong>same</strong> in patients chronically dialyzed with either high- or low-flux dialysis membranes. This was also found in the Membrane Permeability Outcome (MPO) study, in which 738 patients on incident HD, separated by serum albumin levels ≤4 and &gt;4 g/dL, were randomly assigned to high- or low-flux dialysis membranes [<a href="#rid103">103</a>]. Overall, there was no difference in survival with either membrane, although there was a nonsignificant trend for increased survival with high flux (RR 0.76, 95% CI 0.56-1.04). Among the subgroup of patients with serum albumin ≤4 g/dL, survival was significantly higher in the high-flux group (hazard ratio [HR] 0.63, 95% CI 0.45-0.90). This is less likely to be a spurious finding, given that this was a prespecified subgroup [<a href="#rid104">104</a>]; nevertheless, this result was not observed in the HEMO trial and should be confirmed by additional studies.</p><p>Although not directly applicable to the chronic setting, the RR for mortality (and recovery of kidney function) also appears to be the same with both high- and low-flux membranes among those with acute kidney injury [<a href="#rid105">105</a>].</p><p class="headingAnchor" id="H18"><span class="h1">HEMODIALYSIS SESSION LENGTH</span><span class="headingEndMark"> — </span>The effect of hemodialysis (HD) session length on mortality independent of conventional markers of dialysis adequacy is unclear among patients undergoing standard, three times per week dialysis therapy. Some observational studies of large databases suggest that increased session length improves survival [<a href="#rid12">12,106,107</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Based upon data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) of 22,000 patients on HD, treatment time that was &gt;240 minutes per session was significantly associated with decreased risk of mortality (relative risk [RR] 0.81) [<a href="#rid12">12</a>]. In addition, a 7 percent lower RR of death was observed with each additional one-half-hour time on dialysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 6593 patients in the Australian/New Zealand registry, the lowest mortality risk was observed in patients with HD session lengths of 4.5 to 4.9 hours [<a href="#rid106">106</a>].</p><p></p><p>These studies did not control for body size, which is usually a determinant of session length. However, support for a role of session length independent of body size was provided by an analysis of data from a large, outpatient dialysis organization that showed that treatment time &lt;240 minutes per session was associated with increased mortality independent of body size (hazard ratio [HR] 1.26) [<a href="#rid108">108</a>].</p><p>A discussion of the effect of prolonged dialysis session length on outcomes, including survival, with nocturnal HD is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1959.html" rel="external">"Outcomes associated with nocturnal hemodialysis"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">CONTROL OF FLUID BALANCE AND HYPERTENSION</span><span class="headingEndMark"> — </span>It is important to determine an accurate dry weight and to achieve this target weight. Chronic fluid overload is associated with increased mortality [<a href="#rid109">109-113</a>].</p><p>A large observational study showed significant associations between both baseline and one-year cumulative fluid overload and increased mortality among outpatients on incident hemodialysis (HD) [<a href="#rid110">110</a>]. Patients were stratified by systolic blood pressure (&lt;130, 130 to 160, and &gt;160 mmHg), and bioimpedance spectroscopy was used to assess fluid status. Fluid overload was defined as ≥15 percent fluid excess for men and ≥13 percent fluid excess for women, and the first measurement was obtained within three months of starting HD. Both fluid overload at initiation and one-year cumulative fluid overload predicted increased mortality across all blood pressure groups. Cumulative fluid overload had the larger effect on mortality (for patients with systolic blood pressure &lt;130 mmHg, hazard ratio [HR] 1.94; for patients with systolic blood pressure 130 to 160 mmHg, HR 1.51; for patients with systolic BP &gt;160 mmHg, HR 1.62). The effect of fluid overload was similar in all groups as stratified by age, sex, body mass index (BMI), and comorbidities including diabetes and heart disease.</p><p>Although this study does not suggest a causal relationship between fluid overload and mortality (cause-specific mortality was not determined), this study and others support a detrimental effect of fluid overload [<a href="#rid114">114</a>].</p><p>Adequate fluid removal depends upon the technical ability to remove excess fluid, the patient's tolerance to the fluid removal rate, and the patient's adherence to fluid-intake restrictions. Shorter dialysis necessitates more rapid fluid removal, which is more likely to induce episodes of hypotension. Hypotension is associated with transient myocardial ischemia and subsequent cardiac stunning that then needs to be treated with fluid administration. The net effect is that true dry weight is never achieved, leading to persistent volume expansion, hypertension, and possible deterioration in left ventricular function. These complications may contribute to the high cardiac mortality in patients on dialysis. (See  <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">"Intradialytic hypotension in an otherwise stable patient"</a>.)</p><p>Dry weight has been defined as not merely the absence of edema but the minimal body sodium content and volume of body water that can be tolerated without inducing hypotension. Gradual fluid removal with longer dialysis permits a greater degree of total fluid loss and more likely attainment of dry weight. As an example, slow dialysis, such as with nocturnal HD, commonly results in normotensive patients who do not require the use of antihypertensive medications. The ability to discontinue drug therapy may be an important component of this regimen since it further minimizes the risk of hypotension as the excess fluid is removed.</p><p>The ability to remove adequate fluid also depends upon the ability of the patient to adhere to fluid-intake restrictions. Some data suggest that psychologic interventions may improve the ability to adhere to such restrictions, although the quality of the medical literature is generally poor [<a href="#rid115">115</a>].</p><p class="headingAnchor" id="H433970018"><span class="h2">Inadequate ultrafiltration</span><span class="headingEndMark"> — </span>Inadequate total body fluid removal may increase the overall risk of death. In one study of over 3000 patients on HD, the relative risk (RR) of death was correlated with ultrafiltration status [<a href="#rid116">116</a>]. In this study, soft-tissue hydration was determined via bioelectric impedance analysis and impedance vector length; a shorter vector length, which was associated with inadequate ultrafiltration, was associated with an increased RR of death. A similar correlation between survival and ultrafiltration was observed in a study from the Netherlands [<a href="#rid58">58</a>].</p><p>Better volume management via intradialytic blood-volume monitoring may improve outcomes, including mortality:</p><p class="bulletIndent1"><span class="glyph">●</span>In a six-month study in which 443 patients were randomly assigned to an intradialytic blood-volume monitoring device and conventional monitoring, mortality and non-access-related hospitalizations were significantly higher with the device [<a href="#rid117">117</a>]. This result may have been due in part to the atypically low hospitalization and mortality rates for the conventionally monitored group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The assessment of volume status by bioimpedance spectroscopy was compared with that by routine clinical practice (ie, control group) among 156 randomly assigned patients [<a href="#rid118">118</a>]. At one year, the left ventricular mass index, the left atrial volume index, and blood pressure values decreased in the bioimpedance spectroscopy group but not in the control group.</p><p></p><p class="headingAnchor" id="H433970024"><span class="h2">Rapid ultrafiltration</span><span class="headingEndMark"> — </span>High ultrafiltration rates have been associated with increased cardiovascular mortality [<a href="#rid13">13,119,120</a>]. All studies found a higher mortality in patients undergoing high rates of ultrafiltration (eg, an ultrafiltration volume &gt;5.7 percent of postdialysis weight [<a href="#rid120">120</a>] or ultrafiltration rates &gt;13 mL/hour/kg [<a href="#rid13">13,119</a>]) (see  <a class="medical medical_review" href="/z/d/html/1922.html" rel="external">"Evaluation of sudden cardiac arrest and sudden cardiac death in patients on dialysis"</a>). This may be due, in part, to repeated episodes of transient myocardial ischemia/stunning that can occur even in patients with normal coronary arteries [<a href="#rid13">13,14</a>]. Based on these mortality data, the Centers for Medicaid and Medicare Services adopted a quality measure targeting an ultrafiltration rate ≤13 mL/hour/kg. This ultrafiltration rate target may complicate the treatment of patients who gain excessive fluid between treatments but has been associated with fewer episodes of intradialytic hypotension [<a href="#rid121">121</a>]. </p><p>Additional study is required to determine the optimal ultrafiltration strategy for thrice weekly HD. Ultrafiltration rate–associated harm may occur at levels less than 13 mL/hour/kg [<a href="#rid12">12,119,122</a>], and observational data suggest that ultrafiltration rate thresholds scaled to weight may lead to worse outcomes in patients with higher body weight [<a href="#rid123">123,124</a>]. (See  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis", section on 'Patient-specific parameters'</a>.)</p><p class="headingAnchor" id="H520250775"><span class="h1">INTERDIALYTIC INTERVAL</span><span class="headingEndMark"> — </span>Long interdialytic intervals that occur over a weekend among patients who are dialyzed on a three times weekly schedule likely contribute to mortality and morbidity. This was suggested by a retrospective analysis of 32,065 patients on hemodialysis (HD) who participated in the End-Stage Renal Disease Clinical Performance Measures Project [<a href="#rid125">125</a>]. This analysis demonstrated an increase in all-cause mortality on the day following the long interval, compared with other days (22.1 versus 18.0 deaths per 100 person-years). After the long interval, there was also an increase in the following (per 100 patient-years):</p><p class="bulletIndent1"><span class="glyph">●</span>Mortality from cardiac causes (10.0 versus 7.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Mortality from infection (2.5 versus 2.1)</p><p class="bulletIndent1"><span class="glyph">●</span>Mortality from cardiac arrest (1.3 versus 1.0)</p><p class="bulletIndent1"><span class="glyph">●</span>Mortality from myocardial infarction (6.3 versus 4.4)</p><p class="bulletIndent1"><span class="glyph">●</span>Admissions for myocardial infarction (6.3 versus 3.9)</p><p class="bulletIndent1"><span class="glyph">●</span>Congestive heart failure (29.9 versus 16.9)</p><p class="bulletIndent1"><span class="glyph">●</span>Stroke (4.7 versus 3.1)</p><p class="bulletIndent1"><span class="glyph">●</span>Dysrhythmia (20.9 versus 11.0)</p><p class="bulletIndent1"><span class="glyph">●</span>Any cardiovascular event (44.2 versus 19.7)</p><p></p><p>The authors were unable to determine whether adverse events occurred before, during, or after the first weekly dialysis sessions.</p><p>These data suggest that the two-day interval is a time of increased risk for cardiovascular and noncardiovascular mortality and morbidity for patients who are on a three times weekly dialysis schedule. Potential reasons for the increased risk were not addressed in this study, but fluid accumulation, hemodynamic changes, and electrolyte abnormalities or changes may contribute, at least to the cardiovascular events. </p><p class="headingAnchor" id="H20"><span class="h1">MALNUTRITION</span><span class="headingEndMark"> — </span>Studies have demonstrated greater medical risk and increased mortality in undernourished and small patients on dialysis (as noted by a low body mass index [BMI]), with hypoalbuminemia and lower plasma levels of urea nitrogen and creatinine than expected from the intensity of dialysis [<a href="#rid91">91,126-128</a>]. As an example, a plasma albumin concentration &lt;4 g/dL (40 g/L) is the single laboratory finding most closely associated with an increased probability of death. The increase in risk is dose dependent, rising modestly at a plasma albumin concentration of 3.5 to 3.9 g/dL (35 to 39 g/L), but being much greater at values &lt;3.0 g/dL (30 g/L)  (<a class="graphic graphic_figure graphicRef70749" href="/z/d/graphic/70749.html" rel="external">figure 3</a>) [<a href="#rid91">91,126,127</a>].</p><p>These observations have primarily been made in patients on maintenance hemodialysis (HD) and may overestimate the effect of hypoalbuminemia since some measurements taken in the weeks to months before death were included. However, a similar relationship between hypoalbuminemia and increased mortality has been demonstrated with peritoneal dialysis (PD) and, although less pronounced than in the figure, with plasma albumin concentrations measured within six weeks of starting dialysis  (<a class="graphic graphic_figure graphicRef60944" href="/z/d/graphic/60944.html" rel="external">figure 4</a>) [<a href="#rid129">129</a>]. (See  <a class="medical medical_review" href="/z/d/html/1855.html" rel="external">"Nutritional status and protein intake in patients on peritoneal dialysis"</a>.)</p><p>The presence of malnutrition prior to the initiation of dialysis is also strongly predictive of increased mortality [<a href="#rid54">54</a>]. Despite this, the presence of associated conditions, particularly comorbid conditions, significantly contributes to mortality, independent of nutritional status. In one study, for example, the outcomes of a total of 153 consecutive patients on PD were analyzed based upon the presence or absence of malnutrition, with or without comorbid conditions [<a href="#rid130">130</a>]. The combined presence of malnutrition plus a comorbid condition was associated with a high mortality, while there is a trend with malnutrition alone for an increase in mortality.</p><p>Conversely, measures of good nutritional status, such as high BMI in combination with normal or high muscle mass, are associated with increased survival [<a href="#rid131">131,132</a>]. As an example, in a study of patients on incident PD, the best survival was observed in those with high BMI and normal or high muscle mass [<a href="#rid131">131</a>].</p><p>As with hypoalbuminemia, a similar incidence of undernutrition has been noted with the use of creatinine production to assess lean body mass in stable patients on maintenance dialysis. In one study, estimated lean body mass was below normal in 47 and 66 percent of patients on HD and PD, respectively [<a href="#rid133">133</a>]. There was a significant correlation between lean body mass and the plasma albumin concentration in the group as a whole; however, there was substantial variability in individual patients.</p><p>Another marker of malnutrition, a low ratio of body weight for height, also predicts mortality in patients on HD. In an analysis of data from nearly 13,000 patients, there was a highly significant inverse relationship between mortality rates and the ratio of body weight for height among those with ratios below the 50<sup>th</sup> percentile [<a href="#rid134">134</a>].</p><p>The association between markers of malnutrition and reduced patient survival does not prove a cause-and-effect relationship. Nevertheless, it constitutes the rationale for attempting to improve nutrition via diet and more intensive dialysis. (See  <a class="medical medical_review" href="/z/d/html/1856.html" rel="external">"Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis"</a>.)</p><p>The meaning of a low plasma albumin concentration may also differ among patients on HD and PD due in part to variations in volume status. The serum albumin among patients on HD is often measured predialysis, a time when volume expansion is maximal; by comparison, the concentration of albumin in the PD population should not vary acutely. Differences in mortality among these two modalities that appear to correlate with albumin levels may therefore instead be due to variations in intravascular volume.</p><p>Although poor nutrition is a common cause of hypoalbuminemia in patients on dialysis, a number of chronic inflammatory conditions can also reduce the serum albumin concentration [<a href="#rid135">135</a>]. This effect appears to be mediated by cytokines, such as interleukin-1 and tumor necrosis factor-alpha, which suppress hepatic albumin synthesis [<a href="#rid136">136</a>]. Thus, the presence of an untreated, underlying inflammatory process may contribute to the decreased survival observed among patients on chronic HD with hypoalbuminemia. (See  <a class="medical medical_review" href="/z/d/html/1939.html" rel="external">"Inflammation in patients with kidney function impairment"</a>.)</p><p>Unlike the general population, some, but not all, studies have shown that being overweight (perhaps a surrogate for "overnutrition") may enhance survival among patients on HD [<a href="#rid132">132,137-143</a>]. In one study of over 1300 patients on HD, every one-unit increase in the BMI was associated with a reduction of 30 percent in the relative risk (RR) of dying [<a href="#rid137">137</a>]. This result may be confounded in part by race and sex since African American females have the highest BMI [<a href="#rid144">144</a>].</p><p>The apparent survival benefit conferred by higher body weight may be limited to older adults (&gt;65 years of age). This was suggested by a prospective analysis of 1749 patients who were stratified by age and BMI [<a href="#rid145">145</a>]. Among 984 patients &lt;65 years of age, the age-standardized mortality rate was 1.7 times higher for patients with a BMI of ≥30 kg/m<sup>2</sup> compared with those with a normal (20 to 24 kg/m<sup>2</sup>) BMI. By contrast, among 765 patients &gt;65 years of age, there was no difference in mortality between individuals in these BMI groups.</p><p>In addition, increasing height itself may contribute to mortality. A prospective study that was conducted from 2001 until 2006 and included 117,644 patients on HD with BMI values ≥12 to ≤60 kg/m<sup>2</sup> suggested that height, adjusted for weight, was directly associated with all-cause mortality and with cardiovascular, infection-related, and cancer mortality [<a href="#rid146">146</a>].</p><p>Obesity has been associated with worse survival outcomes among patients on PD in other studies [<a href="#rid140">140,147</a>].</p><p class="headingAnchor" id="H21"><span class="h1">CHRONIC HEMODIALYSIS ACCESS</span><span class="headingEndMark"> — </span>Arteriovenous fistulas have advantages over arteriovenous grafts and central venous catheters, with some evidence suggesting a survival benefit with fistulas. (See  <a class="medical medical_review" href="/z/d/html/115151.html" rel="external">"Approach to the adult patient needing vascular access for chronic hemodialysis"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">DISORDERS OF MINERAL METABOLISM</span><span class="headingEndMark"> — </span>A number of reports have delineated an increased risk of all-cause and cardiovascular mortality in patients with disorders of mineral metabolism [<a href="#rid148">148-152</a>]. Although not found in all studies, the association with decreased survival primarily involves increased phosphate, calcium, calcium x phosphate product, and/or parathyroid hormone (PTH) levels. These in turn may be associated with accelerated atherosclerosis, arterial calcification, and an increased risk of adverse cardiovascular outcomes and death.</p><p>This was shown in a retrospective analysis of a database of over 40,000 patients on hemodialysis (HD) in which the relative risks (RRs) of death were determined for multiple categories of serum phosphate, calcium, calcium x phosphate product, and PTH [<a href="#rid148">148</a>]. After multivariate adjustments, the lowest RRs of death were observed among patients with serum phosphate concentrations between 3 and 5 mg/dL (0.97 and 1.61 mmol/L), serum calcium concentrations &lt;8.0 mg/dL (2.0 mmol/L), a calcium x phosphate product of &lt;45 to 50 mg<sup>2</sup>/dL<sup>2</sup>, and intact PTH &lt;600 pg/mL (600 ng/L).</p><p>Concentrations of these substances that were above each of these levels were significantly associated with decreased survival. Compared with serum phosphate concentrations between 4.0 and 5.0 mg/dL (1.29 and 1.61 mmol/L), for example, an increased RR of death was noted for serum phosphate levels &gt;5.0 mg/dL (1.61 mmol/L): The RR increased gradually from 1.07 to 2.02 at serum phosphate levels of 5.0 to 6.0 and ≥9.0 mg/dL, respectively.</p><p>Given that the calcium result may have been confounded by the tendency of calcium levels to increase or decrease with reciprocal changes in serum phosphate, the risk of death was also determined for calcium levels measured within serum phosphate categories of 4 to 5, 5 to 6, 6 to 7, and 7 to 8 mg/dL. Within each phosphate category, higher calcium levels were associated with significant increases in mortality risk.</p><p>Analyses of similar large databases have also found that increased levels of calcium, phosphate, and/or PTH had significant adverse effects upon survival [<a href="#rid149">149-151,153,154</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 25,588 patients participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS), the highest mortality was noted for those with calcium levels &gt;10.0 mg/dL, phosphorus levels &gt;7.0 mg/dL, and PTH levels &gt;600 pg/mL [<a href="#rid154">154</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 1629 patients on incident HD and peritoneal dialysis (PD) from the Netherlands, phosphate and calcium x phosphate levels above Kidney Disease Outcomes Quality Initiative (KDOQI) guideline levels were associated with increased mortality risks in both patient groups [<a href="#rid151">151</a>].</p><p></p><p>However, other studies have noted that low PTH and calcium levels are associated with an increase or no effect on mortality [<a href="#rid155">155-158</a>]. A possible explanation for these disparate findings includes variations in study design, differences in population evaluated, and the use of only single measurements of calcium, phosphate, and PTH.</p><p>To better assess the association between mortality and changes in calcium, phosphate, and PTH over time, two studies have been performed to assess survival compared with differences over time in changes in bone mineral elements [<a href="#rid159">159,160</a>]. One prospective study, for example, was performed of 1006 patients on incident HD and PD in whom longitudinal changes in bone mineral parameters were assessed [<a href="#rid159">159</a>]. PTH levels decreased over the course of one year, while calcium and phosphate levels and the calcium x phosphate product increased over the first six months and then remained stable. After adjustment for comorbidity and other confounding variables, an increased risk of death was observed with the highest quartile for phosphate levels, using both baseline and time-dependent values (hazard ratio [HR] 1.57, 95% CI 1.07-2.30). By comparison, an increased mortality risk with the highest quartile for calcium, calcium x phosphate product, and PTH levels was only observed with the time-dependent values.</p><p>In addition to phosphate, calcium, calcium x phosphate product, and PTH levels, additional serum laboratory values related to bone disease are associated with survival among dialysis:</p><p class="bulletIndent1"><span class="glyph">●</span>Fibroblast growth factor-23 (FGF-23) is an osteoblastic hormone involved in the regulation of phosphate and vitamin D. With increasing phosphate levels in those with increasing kidney dysfunction, elevations in FGF-23 levels stimulate the renal excretion of phosphate and inhibit the synthesis of 1,25-dihydroxyvitamin D. As with increased phosphate levels, elevated FGF-23 levels are associated with increased mortality among patients with end-stage kidney disease (ESKD). This was shown in a nested case-control study of 200 patients who died and 200 patients who survived the first year of HD [<a href="#rid161">161</a>]. Based upon multivariable analysis, increasing FGF-23 levels were associated with an increasing risk of death when analyzed via either a continuous scale or quartiles. As an example, the risk of death was significantly higher in patients with the highest FGF-23 levels (quartile 4) compared with the group with the lowest FGF-23 levels (quartile 1) (odds ratio [OR] 5.7, 95% CI 2.6-12.6).</p><p></p><p class="bulletIndent1">FGF-23 has also been associated with cardiovascular events and mortality in predialysis chronic kidney disease (CKD) patients [<a href="#rid162">162,163</a>], kidney transplant patients [<a href="#rid164">164</a>], and non-CKD patients [<a href="#rid165">165</a>]. Further studies are needed to define the role of FGF-23.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased mortality is described in patients on dialysis with elevated serum alkaline phosphate levels [<a href="#rid166">166,167</a>]. In one study, levels of alkaline phosphatase ≥120 units/L were associated with an increased risk of death (HR 1.25, 95% CI 1.21-1.29) [<a href="#rid166">166</a>].</p><p></p><p>These observational studies suggest that the many interventions utilized to maintain target calcium, phosphate, and PTH levels must be adequately assessed in rigorous trials to help determine their effect upon survival in patients with ESKD. These interventions include low-phosphate diets, calcium- and non-calcium-based phosphate binders, vitamin D analogs, and/or calcimimetics.</p><p>Some of these issues are discussed in detail separately: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7222.html" rel="external">"Vascular calcification in chronic kidney disease"</a>.)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">ACHIEVING MULTIPLE CLINICAL PERFORMANCE MEASURES</span><span class="headingEndMark"> — </span>Meeting specific goals for some clinical parameters has a beneficial impact upon survival in dialysis patients. Prominent examples include attaining and maintaining target levels for either hemodialysis (HD) dose or hemoglobin concentration. (See <a class="local">'Adequacy of dialysis'</a> above.)</p><p>Practically all studies that have examined the effect upon survival of achieving clinical performance goals have evaluated benefits due to a single measure of clinical care. There is evidence that achieving multiple clinical targets may be associated with superior survival outcomes versus those observed with attaining fewer clinical targets or only one [<a href="#rid168">168-173</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Among nearly 200,000 patients, the risk of death during the first year of HD correlated with having met zero, one, two, or three of the following guideline goals at initiation of HD: use of an arteriovenous fistula or graft at initiation, hemoglobin level ≥11 g/dL, and goal albumin level [<a href="#rid173">173</a>]. Compared with those who met no goal, the risk of death was significantly lower among those who met one (0.81, 0.80-0.83), two (0.53, 0.41-0.56), or three goals (0.34, 0.30-0.39). A lower mortality rate was also observed in those who met each individual goal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During a 12-month follow-up period in a retrospective study of 15,287 patients on HD, death or hospitalization were compared with achieving target levels for hemoglobin (≥11 g/dL), serum albumin levels (3.7 g/dL by bromocresol purple laboratory method), use of a fistula for vascular access, and a single-pool Kt/V urea of ≥1.2 [<a href="#rid168">168</a>]. Seven, 24, 39, 24, and 6 percent of patients met four, three, two, one, and zero targets, respectively. There was a significantly increased risk of death and hospitalization among those in whom targets were not met, which increased with each specific target that was not achieved. Compared with meeting all four targets:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjusted hazard ratios [HRs] for death were 1.9 (95% CI 1.4-2.6), 2.6 (95% CI 1.9-3.5), 3.5 (95% CI 2.6-4.7), and 4.6 (95% CI 3.3-6.4) for those who met three, two, one, and zero targets, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjusted HRs for hospitalization were 1.1 (95% CI 0.98-1.3), 1.3 (95% CI 1.1-1.5), 1.5 (95% CI 1.3-1.7), and 1.6 (95% CI 1.4-1.9), respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective analysis of 13,792 patients on incident HD evaluated the correlation between survival and achieving Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines for single-pool Kt/V, hematocrit, serum albumin, calcium, phosphate, and parathyroid hormone (PTH) level [<a href="#rid170">170</a>]. Compared with not achieving any one target, the adjusted HRs for mortality were 0.11 (95% CI 0.06-0.19), 0.19 (95% CI 0.15-0.25), 0.30 (95% CI 0.24-0.37), 0.39 (95% CI 0.31-0.49), 0.52 (95% CI 0.42-0.65), and 0.74 (95% CI 0.49-0.93) for those who met six, five, four, three, two, and one targets, respectively. By comparison, an increased mortality was associated with achieving the blood pressure goal (predialysis &lt;140/90 mmHg; 1.90, 95% CI 1.73-2.10).</p><p></p><p>These studies are limited in part because of their design, underreporting of comorbid conditions, and unknown incidence of disease severity. However, these results are generally consistent with other, primarily observational studies showing increased risk of death and hospitalization with decreased dialysis dose or hemoglobin levels, low serum albumin concentration, abnormal mineral metabolism, and HD with a vascular access other than an arteriovenous fistula. This suggests that quality improvement measures should be implemented to increase the number of those who meet multiple performance measures.</p><p class="headingAnchor" id="H1617093440"><span class="h1">MODALITIES OF KIDNEY REPLACEMENT THERAPY</span></p><p class="headingAnchor" id="H24"><span class="h2">Hemodialysis versus peritoneal dialysis</span><span class="headingEndMark"> — </span>The data described above were almost entirely from patients treated with maintenance hemodialysis (HD). Survival of patients on HD versus peritoneal dialysis (PD) is presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1844.html" rel="external">"Dialysis modality and patient outcome"</a>.)</p><p>With PD, there is increasing evidence that increased survival is associated with centers that are relatively more experienced with PD [<a href="#rid174">174-176</a>]. In one observational study of outcomes in large dialysis organizations, an increased mortality risk was observed in patients being treated in organizations with the lowest rates of PD use [<a href="#rid176">176</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Home hemodialysis</span><span class="headingEndMark"> — </span>Home HD is generally associated with higher survival rates compared with in-center HD. Improved survival is noted despite adjustments for age, diagnosis, comorbidity, and sex compared with in-center HD. (See  <a class="medical medical_review" href="/z/d/html/1874.html" rel="external">"Choosing home hemodialysis for end-stage kidney disease"</a>.) </p><p class="headingAnchor" id="H26"><span class="h2">Alternative forms of hemodialysis</span><span class="headingEndMark"> — </span>Although undergoing intense study, no significant conclusions can be drawn concerning the effect on survival of nocturnal HD or short daily HD. (See  <a class="medical medical_review" href="/z/d/html/1904.html" rel="external">"Technical aspects of nocturnal hemodialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1898.html" rel="external">"Short daily hemodialysis"</a>.)</p><p class="headingAnchor" id="H116499730"><span class="h2">Hemodiafiltration</span><span class="headingEndMark"> — </span>HDF is not commonly used in the United States but is readily available in some countries. In contrast to conventional HD, HDF is a form of kidney replacement therapy that predominantly uses convective clearance along with some diffusive clearance to remove retained solutes. As such it has the potential to remove more middle molecules. The mortality associated with HDF compared with HD is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1937.html" rel="external">"Alternative kidney replacement therapies in end-stage kidney disease", section on 'Mortality'</a>.) </p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Although maintenance dialysis prevents death from uremia, mortality among patients with end-stage kidney disease (ESKD) remains high. Patients on dialysis have a substantially higher multivariable-adjusted mortality than patients not on dialysis who have cancer, diabetes, or cardiovascular disease. However, mortality rates among patients with ESKD have improved over time. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of death</strong> – Among patients with ESKD, cardiovascular disease accounts for approximately 50 percent of deaths. Infections are the second most common cause of death, followed by withdrawal from dialysis. (See <a class="local">'Causes of death'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors not related to dialysis</strong> – A large number of risk factors that are unrelated to the dialysis procedure have been associated with decreased survival among patients on dialysis. These include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid conditions such as diabetes and cardiovascular disease (see <a class="local">'Comorbid conditions'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Type of underlying kidney disease (see <a class="local">'Underlying kidney disease'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of residual kidney function (see <a class="local">'Residual kidney function'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Malnutrition (see <a class="local">'Malnutrition'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Frailty (see <a class="local">'Others'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Disorders of mineral metabolism (see <a class="local">'Disorders of mineral metabolism'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors related to dialysis</strong> – Factors associated with the dialysis procedure also correlate with decreased survival. These factors include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inadequate dialysis (see <a class="local">'Adequacy of dialysis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Shorter hemodialysis (HD) session time (see <a class="local">'Hemodialysis session length'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Inadequate total body fluid removal (see <a class="local">'Inadequate ultrafiltration'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Rapid ultrafiltration rates (see <a class="local">'Rapid ultrafiltration'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Long interdialytic intervals (see <a class="local">'Interdialytic interval'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefit of multiple clinical performance</strong> <strong>measures</strong> – Most studies of patients on dialysis that have examined the effect upon survival of achieving clinical performance goals have evaluated benefits due to a single measure of clinical care. There is evidence that achieving multiple clinical targets may be associated with superior survival outcomes versus those observed with attaining fewer clinical targets or only one. (See <a class="local">'Achieving multiple clinical performance measures'</a> above.) </p><p></p><p class="headingAnchor" id="H1802963818"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William Henrich, MD, MACP and Lionel U Mailloux, MD, FACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2018.</li><li class="breakAll">United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022. Available at: https://usrds-adr.niddk.nih.gov/2022.</li><li><a class="nounderline abstract_t">Chertow GM, Johansen KL, Lew N, et al. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 2000; 57:1176.</a></li><li><a class="nounderline abstract_t">Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2007; 2:999.</a></li><li><a class="nounderline abstract_t">Szczech LA, Klassen PS, Chua B, et al. Associations between CMS's Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units. Kidney Int 2006; 69:2094.</a></li><li><a class="nounderline abstract_t">Garg PP, Frick KD, Diener-West M, Powe NR. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation. N Engl J Med 1999; 341:1653.</a></li><li><a class="nounderline abstract_t">Levinsky NG. Quality and equity in dialysis and renal transplantation. N Engl J Med 1999; 341:1691.</a></li><li><a class="nounderline abstract_t">Irvin RA. Quality of care differences by ownership in United States renal dialysis facilities. ASAIO J 2000; 46:775.</a></li><li><a class="nounderline abstract_t">Devereaux PJ, Schünemann HJ, Ravindran N, et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. JAMA 2002; 288:2449.</a></li><li><a class="nounderline abstract_t">Harley KT, Streja E, Rhee CM, et al. Nephrologist caseload and hemodialysis patient survival in an urban cohort. J Am Soc Nephrol 2013; 24:1678.</a></li><li><a class="nounderline abstract_t">Yan G, Norris KC, Xin W, et al. Facility size, race and ethnicity, and mortality for in-center hemodialysis. J Am Soc Nephrol 2013; 24:2062.</a></li><li><a class="nounderline abstract_t">Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69:1222.</a></li><li><a class="nounderline abstract_t">Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 2011; 79:250.</a></li><li><a class="nounderline abstract_t">McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease - a new aspect of cardiovascular disease. Blood Purif 2010; 29:105.</a></li><li><a class="nounderline abstract_t">Collins AJ, Foley RN, Herzog C, et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 2010; 55:S1.</a></li><li><a class="nounderline abstract_t">Bloembergen WE, Port FK, Mauger EA, Wolfe RA. Causes of death in dialysis patients: racial and gender differences. J Am Soc Nephrol 1994; 5:1231.</a></li><li><a class="nounderline abstract_t">Cohen LM, McCue JD, Germain M, Kjellstrand CM. Dialysis discontinuation. A 'good' death? Arch Intern Med 1995; 155:42.</a></li><li><a class="nounderline abstract_t">Wallen MD, Radhakrishnan J, Appel G, et al. An analysis of cardiac mortality in patients with new-onset end-stage renal disease in New York State. Clin Nephrol 2001; 55:101.</a></li><li><a class="nounderline abstract_t">O'Seaghdha CM, Foley RN. Septicemia, access, cardiovascular disease, and death in dialysis patients. Perit Dial Int 2005; 25:534.</a></li><li><a class="nounderline abstract_t">Chong CH, Au EH, Davies CE, et al. Long-term Trends in Infection-Related Mortality in Adults Treated With Maintenance Dialysis. Am J Kidney Dis 2023; 82:597.</a></li><li><a class="nounderline abstract_t">Introduction and summary. Proceedings from the Morbidity, Mortality and Prescription of Dialysis Symposium, Dallas, Tx, September 15 to 17, 1989. Am J Kidney Dis 1990; 15:375.</a></li><li><a class="nounderline abstract_t">Collins AJ, Hanson G, Umen A, et al. Changing risk factor demographics in end-stage renal disease patients entering hemodialysis and the impact on long-term mortality. Am J Kidney Dis 1990; 15:422.</a></li><li><a class="nounderline abstract_t">Mailloux LU, Napolitano B, Bellucci AG, et al. The impact of co-morbid risk factors at the start of dialysis upon the survival of ESRD patients. ASAIO J 1996; 42:164.</a></li><li><a class="nounderline abstract_t">Merkus MP, Jager KJ, Dekker FW, et al. Predictors of poor outcome in chronic dialysis patients: The Netherlands Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group. Am J Kidney Dis 2000; 35:69.</a></li><li><a class="nounderline abstract_t">Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14:3270.</a></li><li><a class="nounderline abstract_t">Centers for Medicare and Medicaid Services, Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006; 48:S1.</a></li><li><a class="nounderline abstract_t">Miskulin D, Bragg-Gresham J, Gillespie BW, et al. Key comorbid conditions that are predictive of survival among hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:1818.</a></li><li><a class="nounderline abstract_t">Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2380.</a></li><li><a class="nounderline abstract_t">Parfrey PS. Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 1993; 21:77.</a></li><li><a class="nounderline abstract_t">Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 1991; 2:2.</a></li><li><a class="nounderline abstract_t">Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17:1085.</a></li><li><a class="nounderline abstract_t">Beddhu S, Zeidel ML, Saul M, et al. The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis. Am J Med 2002; 112:696.</a></li><li><a class="nounderline abstract_t">Miskulin DC, Meyer KB, Martin AA, et al. Comorbidity and its change predict survival in incident dialysis patients. Am J Kidney Dis 2003; 41:149.</a></li><li><a class="nounderline abstract_t">Mailloux LU, Bellucci AG, Napolitano B, et al. Survival estimates for 683 patients starting dialysis from 1970 through 1989: identification of risk factors for survival. Clin Nephrol 1994; 42:127.</a></li><li><a class="nounderline abstract_t">Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.</a></li><li><a class="nounderline abstract_t">Hirsch DJ, West ML, Cohen AD, Jindal KK. Experience with not offering dialysis to patients with a poor prognosis. Am J Kidney Dis 1994; 23:463.</a></li><li><a class="nounderline abstract_t">Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007; 146:177.</a></li><li><a class="nounderline abstract_t">van Dijk PC, Jager KJ, de Charro F, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001; 16:1120.</a></li><li><a class="nounderline abstract_t">Goodkin DA, Young EW, Kurokawa K, et al. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004; 44:16.</a></li><li><a class="nounderline abstract_t">Yoshino M, Kuhlmann MK, Kotanko P, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006; 17:3510.</a></li><li><a class="nounderline abstract_t">van Dijk PC, Zwinderman AH, Dekker FW, et al. Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe. Kidney Int 2007; 71:53.</a></li><li><a class="nounderline abstract_t">Bleyer AJ, Hylander B, Sudo H, et al. An international study of patient compliance with hemodialysis. JAMA 1999; 281:1211.</a></li><li><a class="nounderline abstract_t">Wong JS, Port FK, Hulbert-Shearon TE, et al. Survival advantage in Asian American end-stage renal disease patients. Kidney Int 1999; 55:2515.</a></li><li><a class="nounderline abstract_t">Tanna MM, Vonesh EF, Korbet SM. Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting. Am J Kidney Dis 2000; 36:1175.</a></li><li><a class="nounderline abstract_t">Eisenstein EL, Sun JL, Anstrom KJ, et al. Do income level and race influence survival in patients receiving hemodialysis? Am J Med 2009; 122:170.</a></li><li><a class="nounderline abstract_t">Bleyer AJ, Tell GS, Evans GW, et al. Survival of patients undergoing renal replacement therapy in one center with special emphasis on racial differences. Am J Kidney Dis 1996; 28:72.</a></li><li><a class="nounderline abstract_t">Mesler DE, McCarthy EP, Byrne-Logan S, et al. Does the survival advantage of nonwhite dialysis patients persist after case mix adjustment? Am J Med 1999; 106:300.</a></li><li><a class="nounderline abstract_t">Robinson BM, Joffe MM, Pisoni RL, et al. Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 2006; 17:2910.</a></li><li><a class="nounderline abstract_t">Kucirka LM, Grams ME, Lessler J, et al. Association of race and age with survival among patients undergoing dialysis. JAMA 2011; 306:620.</a></li><li><a class="nounderline abstract_t">Mehrotra R, Kermah D, Fried L, et al. Racial differences in mortality among those with CKD. J Am Soc Nephrol 2008; 19:1403.</a></li><li><a class="nounderline abstract_t">Wolf M, Betancourt J, Chang Y, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19:1379.</a></li><li><a class="nounderline abstract_t">Kimmel PL, Peterson RA, Weihs KL, et al. Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int 1998; 54:245.</a></li><li><a class="nounderline abstract_t">Kimmel PL, Fwu CW, Eggers PW. Segregation, income disparities, and survival in hemodialysis patients. J Am Soc Nephrol 2013; 24:293.</a></li><li><a class="nounderline abstract_t">Chung SH, Lindholm B, Lee HB. Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. Perit Dial Int 2000; 20:19.</a></li><li><a class="nounderline abstract_t">Mc Causland FR, Waikar SS, Brunelli SM. Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients. Kidney Int 2012; 82:204.</a></li><li><a class="nounderline abstract_t">Rambod M, Tolouian R. Dietary sodium and clinical outcome in hemodialysis: where do we stand and what is next? Kidney Int 2012; 82:130.</a></li><li><a class="nounderline abstract_t">Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38:85.</a></li><li><a class="nounderline abstract_t">Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15:1061.</a></li><li><a class="nounderline abstract_t">Vilar E, Wellsted D, Chandna SM, et al. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 2009; 24:2502.</a></li><li><a class="nounderline abstract_t">Shafi T, Jaar BG, Plantinga LC, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 2010; 56:348.</a></li><li><a class="nounderline abstract_t">Marquez IO, Tambra S, Luo FY, et al. Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol 2011; 6:290.</a></li><li><a class="nounderline abstract_t">Benz RL, Pressman MR, Hovick ET, Peterson DD. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis 2000; 35:1052.</a></li><li><a class="nounderline abstract_t">Unruh ML, Buysse DJ, Dew MA, et al. Sleep quality and its correlates in the first year of dialysis. Clin J Am Soc Nephrol 2006; 1:802.</a></li><li><a class="nounderline abstract_t">McClellan WM, Wasse H, McClellan AC, et al. Treatment center and geographic variability in pre-ESRD care associate with increased mortality. J Am Soc Nephrol 2009; 20:1078.</a></li><li><a class="nounderline abstract_t">Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18:3164.</a></li><li><a class="nounderline abstract_t">Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3:133.</a></li><li><a class="nounderline abstract_t">Brunelli SM, Joffe MM, Israni RK, et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:777.</a></li><li><a class="nounderline abstract_t">Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70:1358.</a></li><li><a class="nounderline abstract_t">Beaubrun AC, Kilpatrick RD, Freburger JK, et al. Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients. J Am Soc Nephrol 2013; 24:1461.</a></li><li><a class="nounderline abstract_t">Desmet C, Beguin C, Swine C, et al. Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications. Am J Kidney Dis 2005; 45:148.</a></li><li><a class="nounderline abstract_t">Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 2004; 44:672.</a></li><li><a class="nounderline abstract_t">Johansen KL, Chertow GM, Jin C, Kutner NG. Significance of frailty among dialysis patients. J Am Soc Nephrol 2007; 18:2960.</a></li><li><a class="nounderline abstract_t">Lee HJ, Son YJ. Prevalence and Associated Factors of Frailty and Mortality in Patients with End-Stage Renal Disease Undergoing Hemodialysis: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2021; 18.</a></li><li><a class="nounderline abstract_t">Unruh ML, Evans IV, Fink NE, et al. Skipped treatments, markers of nutritional nonadherence, and survival among incident hemodialysis patients. Am J Kidney Dis 2005; 46:1107.</a></li><li><a class="nounderline abstract_t">O'Hare AM, Tawney K, Bacchetti P, Johansen KL. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis 2003; 41:447.</a></li><li><a class="nounderline abstract_t">Stack AG, Molony DA, Rives T, et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45:690.</a></li><li><a class="nounderline abstract_t">Matsuzawa R, Matsunaga A, Wang G, et al. Habitual physical activity measured by accelerometer and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2012; 7:2010.</a></li><li><a class="nounderline abstract_t">Johansen KL, Kaysen GA, Dalrymple LS, et al. Association of physical activity with survival among ambulatory patients on dialysis: the Comprehensive Dialysis Study. Clin J Am Soc Nephrol 2013; 8:248.</a></li><li><a class="nounderline abstract_t">Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20:872.</a></li><li><a class="nounderline abstract_t">Kshirsagar AV, Craig RG, Moss KL, et al. Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int 2009; 75:746.</a></li><li><a class="nounderline abstract_t">Ramirez SP, Albert JM, Blayney MJ, et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009; 20:1094.</a></li><li><a class="nounderline abstract_t">Lin JL, Lin-Tan DT, Hsu CW, et al. Association of blood lead levels with mortality in patients on maintenance hemodialysis. Am J Med 2011; 124:350.</a></li><li><a class="nounderline abstract_t">Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005; 45:A5.</a></li><li><a class="nounderline abstract_t">Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 1982; 22:304.</a></li><li><a class="nounderline abstract_t">Held PJ, Levin NW, Bovbjerg RR, et al. Mortality and duration of hemodialysis treatment. JAMA 1991; 265:871.</a></li><li><a class="nounderline abstract_t">Woods JD, Port FK, Stannard D, et al. Comparison of mortality with home hemodialysis and center hemodialysis: a national study. Kidney Int 1996; 49:1464.</a></li><li><a class="nounderline abstract_t">Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28:526.</a></li><li><a class="nounderline abstract_t">Laird NM, Berkey CS, Lowrie EG. Modeling success or failure of dialysis therapy: the National Cooperative Dialysis Study. Kidney Int Suppl 1983; :S101.</a></li><li><a class="nounderline abstract_t">Parker TF, Laird NM, Lowrie EG. Comparison of the study groups in the National Cooperative Dialysis Study and a description of morbidity, mortality, and patient withdrawal. Kidney Int Suppl 1983; :S42.</a></li><li><a class="nounderline abstract_t">Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994; 23:272.</a></li><li><a class="nounderline abstract_t">Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.</a></li><li><a class="nounderline abstract_t">Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:661.</a></li><li><a class="nounderline abstract_t">Parker TF 3rd, Husni L, Huang W, et al. Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 1994; 23:670.</a></li><li><a class="nounderline abstract_t">Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50:550.</a></li><li><a class="nounderline abstract_t">McClellan WM, Soucie JM, Flanders WD. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol 1998; 9:1940.</a></li><li><a class="nounderline abstract_t">Chertow GM, Owen WF, Lazarus JM, et al. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 1999; 56:1872.</a></li><li><a class="nounderline abstract_t">Port FK, Ashby VB, Dhingra RK, et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13:1061.</a></li><li><a class="nounderline abstract_t">Gotch FA, Levin NW, Port FK, et al. Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean. Am J Kidney Dis 1997; 30:1.</a></li><li><a class="nounderline abstract_t">Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.</a></li><li><a class="nounderline abstract_t">Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003; 14:1863.</a></li><li><a class="nounderline abstract_t">Wolfe RA, Hulbert-Shearon TE, Ashby VB, et al. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis 2005; 45:127.</a></li><li><a class="nounderline abstract_t">Paniagua R, Amato D, Vonesh E, et al. Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial. Kidney Int 2005; 67:1093.</a></li><li><a class="nounderline abstract_t">Locatelli F, Martin-Malo A, Hannedouche T, et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:645.</a></li><li><a class="nounderline abstract_t">Cheung AK, Greene T. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:462.</a></li><li><a class="nounderline abstract_t">Alonso A, Lau J, Jaber BL. Biocompatible hemodialysis membranes for acute renal failure. Cochrane Database Syst Rev 2005; :CD005283.</a></li><li><a class="nounderline abstract_t">Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006; 69:1229.</a></li><li><a class="nounderline abstract_t">Tentori F, Zhang J, Li Y, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2012; 27:4180.</a></li><li><a class="nounderline abstract_t">Flythe JE, Curhan GC, Brunelli SM. Shorter length dialysis sessions are associated with increased mortality, independent of body weight. Kidney Int 2013; 83:104.</a></li><li><a class="nounderline abstract_t">Flythe JE, Kshirsagar AV, Falk RJ, Brunelli SM. Associations of Posthemodialysis Weights above and below Target Weight with All-Cause and Cardiovascular Mortality. Clin J Am Soc Nephrol 2015; 10:808.</a></li><li><a class="nounderline abstract_t">Zoccali C, Moissl U, Chazot C, et al. Chronic Fluid Overload and Mortality in ESRD. J Am Soc Nephrol 2017; 28:2491.</a></li><li><a class="nounderline abstract_t">Wizemann V, Wabel P, Chamney P, et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009; 24:1574.</a></li><li><a class="nounderline abstract_t">Chazot C, Wabel P, Chamney P, et al. Importance of normohydration for the long-term survival of haemodialysis patients. Nephrol Dial Transplant 2012; 27:2404.</a></li><li><a class="nounderline abstract_t">Kim YJ, Jeon HJ, Kim YH, et al. Overhydration measured by bioimpedance analysis and the survival of patients on maintenance hemodialysis: a single-center study. Kidney Res Clin Pract 2015; 34:212.</a></li><li><a class="nounderline abstract_t">Flythe JE. Turning the Tide: Improving Fluid Management in Dialysis through Technology. J Am Soc Nephrol 2017; 28:2260.</a></li><li><a class="nounderline abstract_t">Sharp J, Wild MR, Gumley AI. A systematic review of psychological interventions for the treatment of nonadherence to fluid-intake restrictions in people receiving hemodialysis. Am J Kidney Dis 2005; 45:15.</a></li><li><a class="nounderline abstract_t">Pillon L, Piccoli A, Lowrie EG, et al. Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. Kidney Int 2004; 66:1266.</a></li><li><a class="nounderline abstract_t">Reddan DN, Szczech LA, Hasselblad V, et al. Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol 2005; 16:2162.</a></li><li><a class="nounderline abstract_t">Hur E, Usta M, Toz H, et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis 2013; 61:957.</a></li><li><a class="nounderline abstract_t">Movilli E, Gaggia P, Zubani R, et al. Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 2007; 22:3547.</a></li><li><a class="nounderline abstract_t">Jadoul M, Thumma J, Fuller DS, et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2012; 7:765.</a></li><li><a class="nounderline abstract_t">Pirkle JL Jr, Comeau ME, Langefeld CD, et al. Effects of weight-based ultrafiltration rate limits on intradialytic hypotension in hemodialysis. Hemodial Int 2018; 22:270.</a></li><li><a class="nounderline abstract_t">Assimon MM, Wenger JB, Wang L, Flythe JE. Ultrafiltration Rate and Mortality in Maintenance Hemodialysis Patients. Am J Kidney Dis 2016; 68:911.</a></li><li><a class="nounderline abstract_t">Raimann JG, Wang Y, Mermelstein A, et al. Ultrafiltration Rate Thresholds Associated With Increased Mortality Risk in Hemodialysis, Unscaled or Scaled to Body Size. Kidney Int Rep 2022; 7:1585.</a></li><li><a class="nounderline abstract_t">Mermelstein A, Raimann JG, Wang Y, et al. Ultrafiltration Rate Levels in Hemodialysis Patients Associated with Weight-Specific Mortality Risks. Clin J Am Soc Nephrol 2023; 18:767.</a></li><li><a class="nounderline abstract_t">Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011; 365:1099.</a></li><li><a class="nounderline abstract_t">Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.</a></li><li><a class="nounderline abstract_t">Goldwasser P, Mittman N, Antignani A, et al. Predictors of mortality in hemodialysis patients. J Am Soc Nephrol 1993; 3:1613.</a></li><li><a class="nounderline abstract_t">Dwyer JT, Larive B, Leung J, et al. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Kidney Int 2005; 68:1766.</a></li><li><a class="nounderline abstract_t">Rocco MV, Jordan JR, Burkart JM. The efficacy number as a predictor of morbidity and mortality in peritoneal dialysis patients. J Am Soc Nephrol 1993; 4:1184.</a></li><li><a class="nounderline abstract_t">Chung SH, Lindholm B, Lee HB. Is malnutrition an independent predictor of mortality in peritoneal dialysis patients? Nephrol Dial Transplant 2003; 18:2134.</a></li><li><a class="nounderline abstract_t">Ramkumar N, Pappas LM, Beddhu S. Effect of body size and body composition on survival in peritoneal dialysis patients. Perit Dial Int 2005; 25:461.</a></li><li><a class="nounderline abstract_t">Kakiya R, Shoji T, Tsujimoto Y, et al. Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 2006; 70:549.</a></li><li><a class="nounderline abstract_t">Keshaviah PR, Nolph KD, Moore HL, et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 1994; 4:1475.</a></li><li><a class="nounderline abstract_t">Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56:1136.</a></li><li><a class="nounderline abstract_t">Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997; 29:658.</a></li><li><a class="nounderline abstract_t">Moshage HJ, Janssen JA, Franssen JH, et al. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987; 79:1635.</a></li><li><a class="nounderline abstract_t">Fleischmann E, Teal N, Dudley J, et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55:1560.</a></li><li><a class="nounderline abstract_t">Leavey SF, McCullough K, Hecking E, et al. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16:2386.</a></li><li><a class="nounderline abstract_t">Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis 2003; 41:925.</a></li><li><a class="nounderline abstract_t">Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among "large" ESRD patients in the United States. Kidney Int 2004; 65:2398.</a></li><li><a class="nounderline abstract_t">Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80:324.</a></li><li><a class="nounderline abstract_t">Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14:2366.</a></li><li><a class="nounderline abstract_t">de Mutsert R, Snijder MB, van der Sman-de Beer F, et al. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007; 18:967.</a></li><li><a class="nounderline abstract_t">Hakim RM, Lowrie E. Obesity and mortality in ESRD: is it good to be fat? Kidney Int 1999; 55:1580.</a></li><li><a class="nounderline abstract_t">Hoogeveen EK, Halbesma N, Rothman KJ, et al. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 2012; 7:280.</a></li><li><a class="nounderline abstract_t">Shapiro BB, Streja E, Ravel VA, et al. Association of Height with Mortality in Patients Undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol 2015; 10:965.</a></li><li><a class="nounderline abstract_t">McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol 2003; 14:2894.</a></li><li><a class="nounderline abstract_t">Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208.</a></li><li><a class="nounderline abstract_t">Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67:1179.</a></li><li><a class="nounderline abstract_t">Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16:1788.</a></li><li><a class="nounderline abstract_t">Noordzij M, Korevaar JC, Boeschoten EW, et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46:925.</a></li><li><a class="nounderline abstract_t">Bellasi A, Di Lullo L, Russo D, et al. Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Noordzij M, Korevaar JC, Bos WJ, et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 2006; 21:2513.</a></li><li><a class="nounderline abstract_t">Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52:519.</a></li><li><a class="nounderline abstract_t">Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16:386.</a></li><li><a class="nounderline abstract_t">Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38:1351.</a></li><li><a class="nounderline abstract_t">Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115.</a></li><li><a class="nounderline abstract_t">Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24:1506.</a></li><li><a class="nounderline abstract_t">Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70:351.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70:771.</a></li><li><a class="nounderline abstract_t">Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584.</a></li><li><a class="nounderline abstract_t">Seiler S, Reichart B, Roth D, et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25:3983.</a></li><li><a class="nounderline abstract_t">McDiarmid SV, Hall TR, Grant EG, et al. Failure of duplex sonography to diagnose hepatic artery thrombosis in a high-risk group of pediatric liver transplant recipients. J Pediatr Surg 1991; 26:710.</a></li><li><a class="nounderline abstract_t">Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22:956.</a></li><li><a class="nounderline abstract_t">Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152:640.</a></li><li><a class="nounderline abstract_t">Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19:2193.</a></li><li><a class="nounderline abstract_t">Drechsler C, Verduijn M, Pilz S, et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011; 6:1752.</a></li><li><a class="nounderline abstract_t">Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med 2006; 145:512.</a></li><li><a class="nounderline abstract_t">Plantinga LC, Fink NE, Jaar BG, et al. Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study. BMC Health Serv Res 2007; 7:5.</a></li><li><a class="nounderline abstract_t">Tentori F, Hunt WC, Rohrscheib M, et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 2007; 18:2377.</a></li><li><a class="nounderline abstract_t">Wingard RL, Pupim LB, Krishnan M, et al. Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program. Clin J Am Soc Nephrol 2007; 2:1170.</a></li><li><a class="nounderline abstract_t">Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1423.</a></li><li><a class="nounderline abstract_t">Slinin Y, Guo H, Gilbertson DT, et al. Meeting KDOQI guideline goals at hemodialysis initiation and survival during the first year. Clin J Am Soc Nephrol 2010; 5:1574.</a></li><li><a class="nounderline abstract_t">Huisman RM, Nieuwenhuizen MG, Th de Charro F. Patient-related and centre-related factors influencing technique survival of peritoneal dialysis in The Netherlands. Nephrol Dial Transplant 2002; 17:1655.</a></li><li><a class="nounderline abstract_t">Schaubel DE, Blake PG, Fenton SS. Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis. Kidney Int 2001; 60:1517.</a></li><li><a class="nounderline abstract_t">Mehrotra R, Khawar O, Duong U, et al. Ownership patterns of dialysis units and peritoneal dialysis in the United States: utilization and outcomes. Am J Kidney Dis 2009; 54:289.</a></li></ol></div><div id="topicVersionRevision">Topic 1847 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://usrds-adr.niddk.nih.gov/2022" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022. Available at: https://usrds-adr.niddk.nih.gov/2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720970" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Vintage, nutritional status, and survival in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17702709" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Serum and dialysate potassium concentrations and survival in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16732194" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Associations between CMS's Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10572154" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10572161" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Quality and equity in dialysis and renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11110280" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Quality of care differences by ownership in United States renal dialysis facilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12435258" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23929773" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nephrologist caseload and hemodialysis patient survival in an urban cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23970120" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Facility size, race and ethnicity, and mortality for in-center hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16609686" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20927040" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093813" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Haemodialysis-induced myocardial stunning in chronic kidney disease - a new aspect of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20082919" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Excerpts from the US Renal Data System 2009 Annual Data Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7873734" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Causes of death in dialysis patients: racial and gender differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7802519" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dialysis discontinuation. A 'good' death?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11269672" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An analysis of cardiac mortality in patients with new-onset end-stage renal disease in New York State.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16411515" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Septicemia, access, cardiovascular disease, and death in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37330132" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term Trends in Infection-Related Mortality in Adults Treated With Maintenance Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2136242" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Introduction and summary. Proceedings from the Morbidity, Mortality and Prescription of Dialysis Symposium, Dallas, Tx, September 15 to 17, 1989.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2333864" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Changing risk factor demographics in end-stage renal disease patients entering hemodialysis and the impact on long-term mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8725682" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The impact of co-morbid risk factors at the start of dialysis upon the survival of ESRD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620547" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Predictors of poor outcome in chronic dialysis patients: The Netherlands Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638926" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17045862" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 2005 Annual Report: ESRD Clinical Performance Measures Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808231" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Key comorbid conditions that are predictive of survival among hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149351" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418631" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cardiac and cerebrovascular disease in chronic uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1832984" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The natural history of myocardial disease in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032201" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12079709" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12500232" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comorbidity and its change predict survival in incident dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955575" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Survival estimates for 683 patients starting dialysis from 1970 through 1989: identification of risk factors for survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1614043" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Survival as an index of adequacy of dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8128951" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Experience with not offering dialysis to patients with a poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17283348" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Octogenarians and nonagenarians starting dialysis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11390709" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486869" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108318" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17091125" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199431" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An international study of patient compliance with hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354301" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Survival advantage in Asian American end-stage renal disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096042" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19185093" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Do income level and race influence survival in patients receiving hemodialysis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8712225" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Survival of patients undergoing renal replacement therapy in one center with special emphasis on racial differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190378" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Does the survival advantage of nonwhite dialysis patients persist after case mix adjustment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16988065" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21828325" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Association of race and age with survival among patients undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385428" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Racial differences in mortality among those with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18400938" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of activated vitamin D and race on survival among hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9648085" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334394" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Segregation, income disparities, and survival in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716579" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22418981" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22743563" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dietary sodium and clinical outcome in hemodialysis: where do we stand and what is next?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431186" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Residual renal function and mortality risk in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034110" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19240122" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20605303" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030575" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Contribution of residual function to removal of protein-bound solutes in hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10845816" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699290" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sleep quality and its correlates in the first year of dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321704" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment center and geographic variability in pre-ESRD care associate with increased mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18003781" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hemoglobin variability and mortality in ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18045862" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hemoglobin level variability: associations with mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337553" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16929251" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744885" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696454" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15384018" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Increased risk of mortality associated with hip fracture in the dialysis population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942958" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Significance of frailty among dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33801577" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prevalence and Associated Factors of Frailty and Mortality in Patients with End-Stage Renal Disease Undergoing Hemodialysis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310577" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Skipped treatments, markers of nutritional nonadherence, and survival among incident hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12552509" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806472" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Association of physical activity with mortality in the US dialysis population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22977216" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Habitual physical activity measured by accelerometer and survival in maintenance hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23124787" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Association of physical activity with survival among ambulatory patients on dialysis: the Comprehensive Dialysis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19297555" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19165177" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Periodontal disease adversely affects the survival of patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357257" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Rosiglitazone is associated with mortality in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21435426" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Association of blood lead levels with mortality in patients on maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15640975" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7176333" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1899455" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Mortality and duration of hemodialysis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8731115" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparison of mortality with home hemodialysis and center hemodialysis: a national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3934452" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A mechanistic analysis of the National Cooperative Dialysis Study (NCDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6345890" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Modeling success or failure of dialysis therapy: the National Cooperative Dialysis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6345897" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Comparison of the study groups in the National Cooperative Dialysis Study and a description of morbidity, mortality, and patient withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8311087" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Urea index and other predictors of hemodialysis patient survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8366899" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172208" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effects of dose of dialysis on morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172209" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840285" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The dose of hemodialysis and patient mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773796" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571796" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Exploring the reverse J-shaped curve between urea reduction ratio and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11912267" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9214395" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490682" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of dialysis dose and membrane flux in maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12819247" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696452" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15698450" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092122" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Effect of membrane permeability on survival of hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19211709" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effect of membrane permeability on survival of hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846749" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Biocompatible hemodialysis membranes for acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16609687" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431708" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23014457" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Shorter length dialysis sessions are associated with increased mortality, independent of body weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25862779" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Associations of Posthemodialysis Weights above and below Target Weight with All-Cause and Cardiovascular Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28473637" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Chronic Fluid Overload and Mortality in ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131355" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The mortality risk of overhydration in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22253067" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Importance of normohydration for the long-term survival of haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26779424" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Overhydration measured by bioimpedance analysis and the survival of patients on maintenance hemodialysis: a single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28620082" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Turning the Tide: Improving Fluid Management in Dialysis through Technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696440" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : A systematic review of psychological interventions for the treatment of nonadherence to fluid-intake restrictions in people receiving hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327426" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930095" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23415416" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17890254" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22403271" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28643378" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effects of weight-based ultrafiltration rate limits on intradialytic hypotension in hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27575009" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Ultrafiltration Rate and Mortality in Maintenance Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35812299" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Ultrafiltration Rate Thresholds Associated With Increased Mortality Risk in Hemodialysis, Unscaled or Scaled to Body Size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36913263" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Ultrafiltration Rate Levels in Hemodialysis Patients Associated with Weight-Specific Mortality Risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21992122" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Long interdialytic interval and mortality among patients receiving hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2333868" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507818" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Predictors of mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16164653" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8305645" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The efficacy number as a predictor of morbidity and mortality in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13679492" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Is malnutrition an independent predictor of mortality in peritoneal dialysis patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16178479" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Effect of body size and body composition on survival in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16788699" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Body fat mass and lean mass as predictors of survival in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8161729" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Lean body mass estimation by creatinine kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469384" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Body weight-for-height relationships predict mortality in maintenance hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9159298" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Determinants of albumin concentration in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3584463" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201023" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11733631" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12722026" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Obesity and survival on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149353" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Survival differences between peritoneal dialysis and hemodialysis among "large" ESRD patients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277152" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Association of body size with outcomes among patients beginning dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12937315" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Effects of body size and body composition on survival in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267739" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201027" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Obesity and mortality in ESRD: is it good to be fat?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223612" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Obesity and mortality risk among younger dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25825484" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Association of Height with Mortality in Patients Undergoing Maintenance Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14569099" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284307" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15698460" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814832" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253734" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33498192" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16799173" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18514987" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8886175" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Hypocalcemia, morbidity, and mortality in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728974" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728786" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Activated injectable vitamin D and hemodialysis survival: a historical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001560" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16738536" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820797" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687639" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525642" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1941463" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Failure of duplex sonography to diagnose hepatic artery thrombosis in a high-risk group of pediatric liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436289" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479029" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667733" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21597029" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Bone alkaline phosphatase and mortality in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015869" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17212829" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634440" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942761" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596117" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Consistent control of mineral and bone disorder in incident hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20538835" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Meeting KDOQI guideline goals at hemodialysis initiation and survival during the first year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12198219" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Patient-related and centre-related factors influencing technique survival of peritoneal dialysis in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576367" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19359081" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Ownership patterns of dialysis units and peritoneal dialysis in the United States: utilization and outcomes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
